Atossa Therapeutics, Inc. (ATOS)

NASDAQ: ATOS · IEX Real-Time Price · USD
1.530
-0.100 (-6.13%)
At close: May 22, 2024, 4:00 PM
1.560
+0.030 (1.96%)
After-hours: May 22, 2024, 7:55 PM EDT
-6.13%
Market Cap 192.41M
Revenue (ttm) n/a
Net Income (ttm) -29.69M
Shares Out 125.76M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,211,391
Open 1.630
Previous Close 1.630
Day's Range 1.510 - 1.640
52-Week Range 0.620 - 2.310
Beta 1.28
Analysts Strong Buy
Price Target 6.00 (+292.16%)
Earnings Date May 13, 2024

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2012
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ATOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ATOS stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 292.16% from the latest price.

Price Target
$6.0
(292.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company's Karisma-Endoxifen clinical trial r...

7 days ago - GlobeNewsWire

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provid...

9 days ago - GlobeNewsWire

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Ta...

15 days ago - GlobeNewsWire

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore t...

23 days ago - GlobeNewsWire

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new stud...

5 weeks ago - GlobeNewsWire

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at th...

5 weeks ago - GlobeNewsWire

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company's Phase 2 EVANGELIN...

6 weeks ago - GlobeNewsWire

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December ...

7 weeks ago - GlobeNewsWire

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epid...

2 months ago - GlobeNewsWire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the L...

2 months ago - GlobeNewsWire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of...

2 months ago - GlobeNewsWire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...

3 months ago - GlobeNewsWire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

3 months ago - GlobeNewsWire

Atossa Therapeutics Issues Letter to Shareholders

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

4 months ago - GlobeNewsWire

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

6 months ago - GlobeNewsWire

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

6 months ago - GlobeNewsWire

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

SEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...

6 months ago - GlobeNewsWire

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

6 months ago - GlobeNewsWire

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery SAN FRANCISCO , Oct. 30, 2023 /PRNewswire/ -- Quantum Lea...

7 months ago - PRNewsWire

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer SEATTLE , Oct. 11, 2023 /PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for...

8 months ago - PRNewsWire

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

SEATTLE, WA / ACCESSWIRE / September 18, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and ind...

8 months ago - Accesswire

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unme...

8 months ago - GlobeNewsWire

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...

10 months ago - GlobeNewsWire

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in ca...

10 months ago - GlobeNewsWire

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

10 months ago - GlobeNewsWire